Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

Marketed as Tauvid by Avid Radiopharmaceuticals, the flortaucipir F18 IV injection is indicated to be used with PET imaging to assess the distribution and density of aggregated tau neurofibrillary tangles.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed goals and current work being conducted by its Diagnostics Accelerator initiative.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The data included more than 2000 brains and approximately 400 cerebrospinal fluid samples, and showed that a protein network module linked to glucose metabolism was also elevated in cerebrospinal fluid in early stages of the disease.

Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.

The association between black individuals and processing speeds may explain the black-white disparities in dementia risk at older age.

The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.

Artificial intelligence unlocks new potential to expand neuroimaging tools and techniques available for disease detection and prevention.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

Evidence continues to increase on the neurological impacts of COVID-19 infection, with patients admitted to the intensive care unit (ICU) showing brain abnormalities on MRI scans.

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation detailed what he foresees the future of Alzheimer and dementia care to look like with telemedicine as a more permanent aspect of care.

The positron emission tomography tau tracer was shown to identify high levels of Alzheimer disease neuropathologic change and neurofibrillary tangles with good sensitivity and specificity.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation spoke to the way the COVID-19 pandemic has transformed the use of telemedicine for the elderly with conditions like Alzheimer and dementia.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the effect that the COVID-19 pandemic has had on the care of patients with Alzheimer disease and dementias.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Cumulative mean systolic blood pressure was associated with those faster declines in memory which were significantly more common in black individuals than white individuals.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

Consumption of whole fruits, vegetables, whole grains, nuts, legumes, fish and olive oil, as well as reduced consumption of red meat and alcohol was observed to assist in preserving cognitive function.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

Will ethical considerations and lack of consent stand in the way of thoroughly exploring the potential of this nondrug therapy?